Though type 2 diabetes (T2D) is a multifactorial syndrome of metabolic dysregulation, current pharmacologic strategies for T2D are focused on the progressive decline in pancreatic β-cell functions with diminished tissue responses to insulin (insulin resistance), closely linked with abnormalities in carbohydrate, fat, and protein metabolism [1]. This evidence concerns the gene INS and Insulin resistance.